From: Hyperprolactinemia with Antipsychotic Drugs in Children and Adolescents
 | Drug | Number | Age (years) | Dose (mg/day) | Duration (weeks) | PRL baseline ng/mL | PRL endpoint ng/mL | % with PRL nl upper limit | % GCM | % GLR | % IM |
---|---|---|---|---|---|---|---|---|---|---|---|
Roke et al. [31] (20) | risperidone | 1390 | 9.7 | 1.6 | 34.8 | 8.2 | 21.6 | 61.7 | 3.0 | 0.5 | 6.2 |
Migliardi et al. [29] | risperidone | 6 (female) | 12.8 (2.3) | 1.9 (1.1) | 52 | 8.4 (2.1) | 23.4 (7.6) | — | — | * | 0 |
 |  | 22 (male) | 10.1 (2.8) | 1.7 (1.2) | 52 | 6.5 (1.9) | 14.9 (8.6) | — | 0 | — | — |
Swadi et al. [30] | risperidone | 11 | <19 | — | 6 | — | — | 91 | — | — | — |
Calarge et al. [32] | risperidone | 107 | 7–17 | — | mean-36 | — | — | 50 | 8 | 11 | 33 |
Roke et al. [31] (7) | olanzapine | 170 | 14.4 | 2.7 | 28 | 11.1 | 24.2 | 31 | 6.2 | 2.8 | 2.4 |
Migliardi et al. [29] | olanzapine | 6 (female) | 14.3 (2.1) | 6.7 (3) | 52 | 8.8 (3.8) | 18 (5.2) | — | — | 0 | 0 |
 |  | 7 (male) | 14 (1.9) | 7.5 (2.5) | 52 | 7.8 (2.4) | 11.3 (4.9) | — | 0 | — | — |
Swadi et al. [30] | olanzapine | 11 | 19 | — | 6 | — | — | 9 | — | — | — |
Roke et al. [31] | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
(5) | quetiapine | 72 | 13.9 | 378.5 | 49.6 | 8.4 | 9.3 | 0 | 0 | 0 | 0 |
(4) | haloperidol | 56 | 12.7 | 7.2 | 6.5 | 7.7 | 29.1 | 90 | 6.7 | 0 | 15.4 |
(3) | pimozide | 46 | 10.3 | 3.7 | 21.2 | 9.3 | 24.7 | 80 | — | — | — |
(2) | clozapine | 30 | 14.5 | 270 | 6 | 9.6 | 11.6 | 0 | 0 | 0 | 0 |
(1) | ziprasidone | 6 | 14.5 (1.8) | 98 (40) | 8.6 (6.6) | 8.6 (6.6) | 12 (8) | 0 | 0 | 0 | 0 |